Articles On Telix Pharmaceuticals (ASX:TLX)

Source: Josep Suria, Shutterstock  Healthcare, one of the biggest and most convoluted sectors in the trade market, is made up of a wide assortment of companies dealing with pharma, medical, fitness and other healthcare facilities and produ...

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is sliding 4.3% today after the company released its FY20 results. The broader S&P/ASX 200 (ASX: XJO) is currently down 2.3% at the time of writing. Telix is a late clinical-stage rad...

Telix Pharmaceuticals (ASX.TLX) has announced that its Japanese subsidiary and partner Kanazawa University have received Clinical Trial Notification clearance to commence a phase one trial of its prostate cancer imaging product TLX5...

Australian company Telix Pharmaceuticals (ASX:TLX) has announced the Ministry of Health of the Czech Republic has become the first European health authority to grant a national authorisation allowing the use of TLX591-CDx.

Summary Telix Pharmaceuticals has obtained national authorisation for its prostate cancer imaging product, TLX591-CDx. With this national authorisation, Czech physicians can use the product even before European marketing approval is gr...

Telix Pharmaceuticals (ASX:TLX) has announced a research cooperation agreement with Heidelberg University Hospital in Germany (UKHD) to develop next-generation theranostic radiopharmaceuticals for urologic oncology.

The OC Micro-Cap Fund was a strong performer during the final quarter of 2020. According to its most recent quarterly update, the fund manager delivered a 17.5% return for investors during the three months ended 31 December. This stretched...

In afternoon trade the S&P/ASX 200 Index (ASX: XJO) is on course to start the week strongly. At the time of writing, the benchmark index is up 0.4% to 6,825.7 points. Four ASX shares that have failed to follow the market higher today a...

25 Jan 2021 - Bio-tech company Telix Pharmaceuticals (ASX:TLX) Phase 3 clinical trial of its renal cancer diagnostic imaging product, Zircon has commenced in the US.

Will the share price of Telix Pharmaceuticals Ltd (ASX: TLX) go up after announcing patient news? What’s Telix? Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using mole...

The Telix Pharmaceuticals Ltd (ASX: TLX) share price has come under pressure on Monday morning and is dropping lower. At the time of writing, the clinical stage biopharmaceutical company’s shares are down 0.5% to $4.51. Why is the Telix sh...

Telix Pharmaceuticals (ASX:TLX) and partner ARTMS have announced they have successfully produced Telix's prostate cancer imaging product, TLX591-CDx (Kit for the preparation of 68Ga-PSMA-11).

Over the past 12 months, the Telix Pharmaceuticals Ltd (ASX: TLX) share price has posted massive gains exceeding 150%. The Telix share price kicked off 2020 at $1.53, closed the year at $3.78 and is currently sitting at $3.86 per share. So...

Telix Pharmaceuticals plans to accelerate development of its radiopharmaceutical to treat the most aggressive form of brain cancer after encouraging ... Read More The post Initial trial results bolster evidence for Telix’s brain cancer trea...

Summary Biopharmaceutical player Telix Pharmaceuticals files a New Drug Submission for TLX591-CDx. The Company has entered in an exclusive scientific and clinical research collaboration with Mauna Kea. The collaboration will build adv...

Biopharma Telix Pharmaceuticals Ltd (ASX: TLX) share price is trading lower this morning, despite the company announcing the completion of its acquisition of Swiss-based company, TheraPharm. At the same time, the company also announced tha...

Summary The intensity of adoption of tech-enabled health solutions has shot up amidst government restrictions and infection risks amidst COVID-19. Burgeoning demand for healthcare products kept healthcare stocks under the spotlight in...

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is trading lower at open today, despite a positive development in its lead drug candidate. Telix announced that the United States Food and Drug Administration (FDA) will begin reviewing...

The TGA has granted Telix Pharmaceuticals' (ASX:TLX) prostate cancer imaging product TLX591-CDx priority review status.

Image Source: Shutterstock Summary Telix Pharmaceuticals announced that its application for TGA determination received priority review status. This status means an acceleration in product review as well as approval timeframe. There i...

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is slipping today, down 2.5% in afternoon trading. This comes despite the company reporting it had received priority review status from Australia’s Therapeutic Goods Administration (TGA)...

In afternoon trade the S&P/ASX 200 Index (ASX: XJO) is on course to record a small gain. At the time of writing, the benchmark index is up 0.2% to 6,603.5 points. Four shares that are climbing more than most today are listed below. Her...

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is racing higher after the company announced a new phase in its drug trials. The company confirmed it will proceed with the Phase III of ProstACT study for its TLX591 drug, a prostate ca...

In afternoon trade the S&P/ASX 200 Index (ASX: XJO) has given back its morning gains and is dropping lower. The benchmark index is currently down 0.3% to 6,570.8 points. Four shares that have not let that hold them back are listed belo...

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is racing higher again on Wednesday after the release of two positive announcements. At the time of writing, the nuclear medicine-focused biopharmaceutical company’s shares are up 9% to...

Australian biotechnology company Telix Pharmaceuticals has announced it will acquire Swiss-German counterpart TheraPharm for its portfolio of potential diagnostics and treatments for haematological diseases like blood cancer.

Summary Telix signed an agreement with Scintec to acquire TheraPharm GmbH. An upfront payment of A$16.5 million would be made for this acquisition. The first and second earn-out component would each be of A$8.1 million, respectively....

30 Nov 2020 - Telix Pharmaceuticals (ASX:TLX) has entered into an agreement with Scintec Diagnostics GmbH to acquire TheraPharm GmbH.

In late morning trade the S&P/ASX 200 Index (ASX: XJO) has given back its early gains and is dropping lower. The benchmark index is currently down 0.2% to 6,587.5 points. Four shares that have not let that hold them back are listed bel...

The Telix Pharmaceuticals Ltd (ASX: TLX) share price has returned from its trading halt and is storming higher again on Monday. In early trade the biopharmaceutical company’s shares are up 8% to a record high of $3.51. Why is the Telix sha...

The All Ordinaries index may be racing higher this month, but its 11% gain pales in comparison to some of the gains being made in November. Three All Ords shares that have been on fire this month are listed below. Here’s why they are rocke...

Telix Pharmaceuticals (ASX:TLX) has filed a new drug application with the US FDA for its radiopharmaceutical targeting ProstateSpecific Membrane Antigen for the imaging of prostate cancer using Positron Emission Tomography.

Summary ASX-listed biopharmaceutical company Telix Pharmaceuticals has received the FDA green light for its TLX591-CDx kit NDA. The biopharmaceutical company also added a priority review request in the NDA submission with the result an...

In late morning trade the S&P/ASX 200 Index (ASX: XJO) is on course to record another strong gain. The benchmark index is currently up 1.1% to 6,639.2 points. Four shares that are climbing more than most today are listed below. Here’s...

Telix Pharmaceuticals Ltd (ASX: TLX) shares are rocketing higher this morning after the company announced the United States Food and Drug Administration (FDA) approved its new drug application (NDA) for a prostate cancer imaging product. I...

Tom Bleakley, BW Equities BUY RECOMMENDATIONS Telix Pharmaceuticals (TLX)   This research and development oncology company has lodged an application to the US Food and Drug Administration for its lead prostate cancer imaging technology. It...

In afternoon trade the S&P/ASX 200 Index (ASX: XJO) is on course to record a very strong gain. At the time of writing, the benchmark index is up a sizeable 2.3% to 6,088.4 points. Four shares that have failed to follow the market highe...

Telix Pharmaceuticals (ASX:TLX) has entered a strategic commercial partnership with China Grand Pharmaceutical and Healthcare Holdings for its portfolio of Molecularly-Targeted Radiation products.

The Melbourne-headquartered biopharmaceutical company is focused on developing a portfolio of clinical-stage oncology products that address significant unmet medical needs in prostate, kidney and brain cancer.

The S&P/ASX 200 Index (ASX: XJO) started the week in fine form and charged higher on Monday. The benchmark index rose 0.4% to end at 5,951.3 points. Four shares that climbed more than most today are listed below. Here’s why they storme...

The Telix Pharmaceuticals Ltd (ASX: TLX) share price has started the week with a bang, rocketing by more than 30% today in welcome news for shareholders. Telix released a positive announcement during mid-afternoon trade, sending its shares...

Here’s the kind of late Friday afternoon announcement anyone who’s left paying attention loves to still be in the office for: “1st Group Limited (ASX:1ST) is pleased to announce it has entered into a strategic commercial partnership with Af...

An additional news report on the recommendation, valuation, forecast and opinion changes for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Au...

In late morning trade the S&P/ASX 200 Index (ASX: XJO) is dropping lower and on course to end its winning streak. The benchmark index is currently down 0.4% to 5,917.6 points. Four shares that have not let that hold them back today are...

The Telix Pharmaceuticals Ltd (ASX: TLX) share price has been a strong performer on Tuesday. In morning trade the clinical-stage biopharmaceutical company’s shares jumped 8% to $1.78. This leaves the Telix share price within sight of its 5...

In late morning trade the S&P/ASX 200 Index (ASX: XJO) is on course to finish the week on a very positive note. The benchmark index is currently up a sizeable 1.6% to 5,971.5 points. Four shares that have failed to follow the market hi...

It has been a disappointing day of trade for the S&P/ASX 200 Index (ASX: XJO) on Thursday. At the time of writing, the benchmark index is down 1% to 5,869.3 points. Four shares that have not let that hold them back are listed below. He...

The market may be dropping lower today but that hasn’t stopped the Telix Pharmaceuticals Ltd (ASX: TLX) share price from charging higher. In morning trade the biopharmaceutical company’s shares are up 3.5% to $1.82. Why is the Telix share...

Telix Pharmaceuticals (ASX:TLX) has submitted a New Drug Application to the US FDA for its radiopharmaceutical targeting Prostate-Specific Membrane Antigen for the imaging of prostate cancer using Positron Emission Tomography.

Nuclear oncology company Telix Pharmaceuticals (ASX:TLX) says the first two patients with advanced lung or ovarian cancer have been dosed ... Read More The post First patients dosed in trial of Telix’s cancer imaging therapy appeared first...